Contrast agent dose and slow/no-reflow in percutaneous coronary interventions : A case-control study of patients with...

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Imaging

Background:

• The slow/no-reflow phenomenon post-percutaneous coronary intervention (PCI) is linked to poor outcomes in non-ST-elevation acute coronary syndrome (NSTEACS).
• Contrast agents used in PCI may contribute to endothelial dysfunction, myocardial damage, and coronary spasms.
• The potential role of contrast agent volume in slow/no-reflow warrants investigation.

Purpose of the Study:

• To investigate the association between contrast agent dose and the incidence of slow/no-reflow.
• To determine if contrast volume is an independent risk factor for slow/no-reflow in NSTEACS patients undergoing PCI.
• To identify a potential threshold for contrast agent dose associated with increased risk.

Main Methods:

• A cohort of 3369 NSTEACS patients undergoing first-time culprit vessel PCI with stenting was analyzed.
• Slow/no-reflow was defined as a post-PCI TIMI flow grade of ≤2.
• Multivariate conditional logistic regression and smooth curve fitting were employed to assess the relationship between contrast dose and slow/no-reflow.

Main Results:

• Contrast agent dose was identified as an independent risk factor for slow/no-reflow, even after adjusting for multiple clinical and procedural variables.
• The risk of slow/no-reflow demonstrated a significant increase with contrast agent dose up to an inflection point of 160 ml.
• The adjusted odds ratio for slow/no-reflow associated with contrast dose was 1.0113 (95% CI: 1.0036-1.0191, p=0.004).

Conclusions:

• Contrast agent volume may be a significant risk factor for developing slow/no-reflow after PCI in NSTEACS patients.
• A contrast dose exceeding 160 ml is associated with a substantially increased risk of the slow/no-reflow phenomenon.
• Optimizing contrast agent administration may be crucial for improving outcomes in NSTEACS patients undergoing PCI.